Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion
EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
January 18, 2024
Primary Completion Date
March 1, 2025
Study Completion Date
March 1, 2026
Conditions
Chronic Hepatitis B
Interventions
DRUG
TVAX-008
TVAX-008
Trial Locations (1)
250000
Shandong Province Public Health Clinical Center, Jinan